Learn everything you need to know about Repaglinide and Metformin-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, ...

Repaglinide belongs to a group of diabetes drugs called meglitinides. It comes as a tablet you take by mouth. Keep reading for details on repaglinide and cost, and how to save money on prescriptions.

May 16, 2003 — In two separate randomized trials presented at the American Academy of Clinical Endocrinology annual meeting, repaglinide was more effective than nateglinide in type 2 diabetes.

Review the side-effects of Repaglinide as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Lean older adults with type 2 diabetes experienced lower ...

Type 2 diabetes care often targets both fasting and post-meal glucose. Repaglinide is a short-acting option for postprandial control. Its safety profile is tightly linked to meal timing, ...

Washington, DC - The FDA and Novo Nordisk have revised the drug interaction section of the insulin secretagogue repaglinide (Prandin ®) to indicate a possible adverse reaction with the lipid-lowering ...

Several markers of inflammation and endothelial dysfunction are associated with the elevated risk of cardiovascular disease (CVD) seen in patients with type 2 diabetes, independently of conventional ...

The benefit of glinides in the treatment of type 2 diabetes is not scientifically proven. Nor do they perform better than other oral antidiabetics (metformin, sulfonylureas). Although glinides have ...

DETROIT, Aug. 13Â -- Caraco Pharmaceutical Laboratories, Ltd., announced today that the US Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug ...

BAGSVAERD, DENMARK--(Marketwired - Jun 18, 2013) - Today, the U.S. Court of Appeals for the Federal Circuit partially affirmed a 2011 District Court decision, with a 2-1 ruling that a claim in a Novo ...